| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 505401 | 1 mg | $175 | ||
| 505402 | 5 mg | $480 | ||
| 505403 | 20 mg | $960 |
| Clone | Rovalpituzumab |
|---|---|
| Application | Flow cytometry, animal model study |
| Host Species | Mammalian cells |
| Format | Liquid |
| Product Description | Anti-Human DLL3 (Rovalpituzumab Biosimilar) |
| Isotype | Human IgG1 |
| Regulatory Status | RUO |
| Clonality | Recombinant |
| Immunogen | Human DLL3 |
| Species specificity | Human |
| Purity | >95% by reducing SDS-PAGE |
| Grade | In vivo |
| Storage Conditions | 4ºC |
| Maximal Shelf Life | 12 months |
| See All Formats | Clone Rovalpituzumab |
Rovalpituzumab, as a therapeutic, is an antibody–drug conjugate (ADC) consisting of a humanized monoclonal antibody directed against delta‑like ligand 3 (DLL3) linked to a potent cytotoxic agent. Structurally, the antibody portion belongs to the immunoglobulin G1 (IgG1) subclass and is composed of two identical heavy chains and two identical light chains connected by disulfide bonds, forming the canonical Y‑shaped structure typical of IgG molecules. The antibody backbone, known as SC16, retains full Fc functionality for structural stability and extended systemic half‑life through recycling by the neonatal Fc receptor (FcRn). The molecule has an approximate molecular mass of 150 kilodaltons (kDa).
The antigen‑binding fragments (Fab) of Rovalpituzumab are derived from murine antibody sequences that confer high‑affinity and selective binding to DLL3, an inhibitory ligand within the Notch signaling pathway that is normally expressed at low levels in healthy tissue but can be found on specific cell membranes.
Anti-Human DLL3 (Rovalpituzumab Biosimilar) TDS
Have a product or application question? Consult our FAQs or contact us.
